- 1、本文档共23页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
15化学药物非临床药代动力学研究技术指导原则.pdf
指导原则编号: 【H】 G P T 5 -1
化学药物非临床药代动力学研究
技术指导原则
二○○五年三月
目 录
一、概述···························································································1
二、基本原则···························································································2
三、试验设计·········································································································2
(一)总体要求··································································································2
(二)生物样本的药物测定方法······································································3
(三)研究项目·········································································································4
四、数据处理与分析····················································································9
五、结果与评价··································································································9
六、常见问题与处理思路···························································································10
七、参考文献······························································································································13
八、附录(生物样品的分析方法)·············································································15
九、著者·····································································································································21
化学药物非临床药代动力学研究技术指导原则
一、概述
非临床药代动力学研究是通过动物体内、外和人体外的研究方法,
揭示药物在体内的动态变化规律,获得药物的基本药代动力学参数,阐
明药物的吸收、分布、代谢和排泄的过程和特点。
非临床药代动力学研究在新药研究开发的评价过程中起着重要作
用。在药效学和毒理学评价中,药物或活性代谢物浓度数据及其相关药
代动力学参数是产生、决定或阐明药效或毒性大小的基础,可提供药物
对靶器官效
文档评论(0)